|Day Low/High||3.74 / 3.97|
|52 Wk Low/High||2.02 / 5.70|
Clinical Research Effort Establishes New Quality Control Standards and Reveals Previously Undetected Risks for Gene Therapy Delivery
New Polymerase and Software Releases Improve Structural Variant Detection, Targeted Sequencing and RNA Sequencing Applications
Presentations will highlight importance of SMRT Sequencing for rare diseases, structural variation, and more
Annual Product and Service Revenue Increases 19% Year over Year
Investors eyeing a purchase of Pacific Biosciences of California Inc stock, but cautious about paying the going market price of $3.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 40 cents.
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Product and Service Revenue Increases by 9% Over Same Period in Previous Year
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
PacBio Sequencing Reveals More Functionally Important Variants; Complete Solution for Structural Variant Detection to be Featured at ASHG Annual Meeting
More than 30 presentations demonstrate utility of SMRT Sequencing for human biomedical applications
Investors considering a purchase of Pacific Biosciences of California Inc shares, but cautious about paying the going market price of $5.10/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2018 put at the $5 strike, which has a bid at the time of this writing of 90 cents.
Product and Service Revenue Increases by 17% Over Same Period in Previous Year
Increases Novogene's Capacity to Run 20 Sequel Systems at a Time
SMRT Sequencing Offers Significant Improvements for Reference Genomes at Much Lower Cost
Pacific Biosciences of California, AveXis and Novavax were among the biotech stock movers in premarket trading on Thursday.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.